The Bio Report

In August, Nabriva Therapeutics won U.S. Food and Drug Administration approval for Xenleta for the treatment of community-acquired bacterial pneumonia in adults. It was the first new antibiotic with a novel mechanism of action approved by the FDA in nearly two decades for the condition. We spoke to Ted Schroeder, CEO of Nabriva about Xenleta’s unique mechanism of action, why it may be less prone to the development of resistance, and why policymakers still need to take additional steps to spur development of novel antibiotics.